000277809 001__ 277809
000277809 005__ 20240229155025.0
000277809 0247_ $$2doi$$a10.1186/s13058-023-01680-x
000277809 0247_ $$2pmid$$apmid:37501086
000277809 0247_ $$2ISSN$$a1465-5411
000277809 0247_ $$2ISSN$$a1465-542X
000277809 037__ $$aDKFZ-2023-01520
000277809 041__ $$aEnglish
000277809 082__ $$a610
000277809 1001_ $$aMöhl, Annika$$b0
000277809 245__ $$aThe impact of cardiovascular disease on all-cause and cancer mortality: results from a 16-year follow-up of a German breast cancer case-control study.
000277809 260__ $$aLondon$$bBioMed Central$$c2023
000277809 3367_ $$2DRIVER$$aarticle
000277809 3367_ $$2DataCite$$aOutput Types/Journal article
000277809 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1691756684_20939
000277809 3367_ $$2BibTeX$$aARTICLE
000277809 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277809 3367_ $$00$$2EndNote$$aJournal Article
000277809 520__ $$aCardiovascular disease (CVD) is the leading cause of death worldwide. The aim of this study was to examine if CVD affects the mortality of women after a breast cancer diagnosis and population controls differently.The analysis included a total of 3,555 women, diagnosed with primary stage 1-3 breast cancer or in situ carcinoma between 2002 and 2005 and 7,334 controls breast cancer-free at recruitment, all aged 50-74 years, who were followed-up in a German breast cancer case-control study until June, 30 2020. Kaplan-Meier and cumulative incidence function were calculated for all-cause mortality and mortality from any cancer, stratified for case-control status and CVD, separately for women aged < 65 and ≥ 65 years. Cox regression and Fine-Gray subdistribution hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for the association between case-control-status, CVD and mortality from all causes/any cancer.The median follow-up was 16.1 years. In total, 1,172 cases (33.0%) and 1,401 initial controls (19.1%) died. CVD prevalence at recruitment was 15.2% in cases and controls. Cases with CVD had the highest and controls without CVD the lowest mortality during the entire observation period in both age groups (< 65 and ≥ 65 years). CVD was identified as a risk factor for all-cause mortality in both cases and controls aged < 65 years (HR 1.22, 95%CI 0.96-1.55 and HR 1.79, 95%CI 1.43-2.24) as well as at ages of ≥ 65 years (HR 1.44, 95%CI 1.20-1.73 and HR 1.59, 95%CI 1.37-1.83). A significant association of CVD and cancer mortality was found only for cases aged ≥ 65 years.CVD was significantly associated with all-cause mortality of both cases and controls and CVD was identified as a risk factor for cancer mortality of cases aged ≥ 65 years at recruitment. Therefore, attention should be paid on monitoring and preventing CVD in breast cancer patients, especially in those diagnosed at older ages.
000277809 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000277809 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000277809 650_7 $$2Other$$aBreast cancer
000277809 650_7 $$2Other$$aCardiovascular disease
000277809 650_7 $$2Other$$aCase–control study
000277809 650_7 $$2Other$$aMortality
000277809 7001_ $$0P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aBehrens, Sabine$$b1$$udkfz
000277809 7001_ $$aFlaßkamp, Fabian$$b2
000277809 7001_ $$aObi, Nadia$$b3
000277809 7001_ $$aKreienbrinck, Annika$$b4
000277809 7001_ $$aHolleczek, Bernd$$b5
000277809 7001_ $$aGali, Kathleen$$b6
000277809 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b7$$udkfz
000277809 7001_ $$aBecher, Heiko$$b8
000277809 773__ $$0PERI:(DE-600)2041618-0$$a10.1186/s13058-023-01680-x$$gVol. 25, no. 1, p. 89$$n1$$p89$$tBreast cancer research$$v25$$x1465-5411$$y2023
000277809 909CO $$ooai:inrepo02.dkfz.de:277809$$pVDB
000277809 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000277809 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000277809 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000277809 9141_ $$y2023
000277809 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-30
000277809 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-30
000277809 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-30
000277809 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-30
000277809 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBREAST CANCER RES : 2022$$d2023-08-26
000277809 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000277809 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000277809 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-26
000277809 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:05:15Z
000277809 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:05:15Z
000277809 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T09:05:15Z
000277809 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000277809 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000277809 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-26
000277809 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBREAST CANCER RES : 2022$$d2023-08-26
000277809 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000277809 980__ $$ajournal
000277809 980__ $$aVDB
000277809 980__ $$aI:(DE-He78)C020-20160331
000277809 980__ $$aUNRESTRICTED